Polycystic ovary syndrome which high risk of venous thromboembolism who was treated with combined oral contraceptive pills. Each type of estrogen exhibits distinct characteristics that differentially influence the risk of venous thromboembolism. Polycystic ovary syndrome, Venous thromboembolism, combined oral contraception, type of estrogen
Conditions
Interventions
Consume combined oral contraception composed of estetrol/Drospirenone for 3 months
,Consume combined oral contraception composed of Ethinylestradiol20mcg/Drospirenone for 3 months
Active Comparator Drug,Active Comparator Drug
Estetrol15mg/Drospirenone,Ethinylestradiol20mcg/Drospirenone
Sponsors
Faculty of medicine prince of songkla university
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Patients with polycystic ovary syndrome who diagnose by Rotterdam criteria 2003
Exclusion criteria
Exclusion criteria: 1. Smoker 2. Pregnancy 3. History of hysterectomy or bilateral salpingo-oophorectomy 4. Previous chemotherapy and radiation therapy 5. Recent use of hormonal drugs within the past 3 months (especially for depot medoxyprogesterone [DMPA] within 9 months) 6. Use of medications that reduce the effectiveness of oral contraceptive (such as Rifampicin, Rifabutin, Barbiturates, Carbamazepine, Lamotrigine, Oxacarbazepine, Phenytoin, Primidone, and Topiramate 7. Other ovarian disorders such as premature ovarian failure 8. Abnormal thyroid function 9. Patients who have undergone gastric bypass surgery for obesity 10. Patients receive anticoagulation such as Warfarin 11. Patients receive antiplatelet such as Aspirin 12. Patients who had history or active condition of VTE 13. Patients who had family history of venous thromboembolism 14. Patients who were diagnosed with thrombophilia (e.g., Factor V Leiden, prothrombin gene mutation, antithrombin deficiency, protein C/S deficiency, antiphospholipid syndrome)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| venous thrombosis marker 3 months value of each markder ,Protein S 3 months measure from serum (value),SHBG 3 months measure from serum (value),Factor VII 3 months measure from serum (value),Factor VIII 3 months measure from serum (value),Factor X 3 months measure from serum (value),D-dimer 3 months measure from serum (value) | — |
Secondary
| Measure | Time frame |
|---|---|
| Vaginal Bleeding pattern each cycle of during consume categorize as schedule bleeding or spottin , Unschedule bleeding or spotting ,Anthropometric 3 months measure as centrimeter | — |
Countries
Thailand
Contacts
Public ContactKrittanai Kuntheekan
Faculty of Medicine, Prince of Songkla University
Outcome results
None listed